Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butantan adjuvanted trivalent influenza vaccine versus high-dose trivalent influenza vaccine in adults aged 60 years and older
ISRCTN13575129Phase 3Active, not recruiting
- Sponsor
- Instituto Butantan
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of IB160-adjuvanted inactivated trivalent influenza vaccine and influenza virus vaccine, split virion in influenza (2 arms), sponsored by Instituto Butantan. Primary endpoints: Geometric mean titer ratio and Seroconversion rate difference. Started Mar 2026; status: active, not recruiting.
02
Drugs
IB160-adjuvanted inactivated trivalent influenza vaccineinfluenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on ISRCTN13575129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13575129.